Novo taps stem cells in hunt for diabetes cure
By Ben Hirschler
LONDON (Reuters) - Danish drugmaker Novo Nordisk A/S is turning to stem cells in the hunt for a cure for diabetes.
The world leader in diabetes care said on Thursday it had launched a new collaboration to develop a treatment for type 1 diabetes by programing stem cells to turn into insulin-producing cells.
The alliance with privately held biotech firm Cellartis and Denmark’s Lund University signals growing interest in stem cell technology within the pharmaceutical industry.
Until now, drugmakers have been wary about the early-stage nature of much stem cell research and anxious about controversy surrounding the use of cells derived from embryos.
But Novo and its partners now believe the technology has advanced to a stage where it may be possible to develop a cell therapy for treating insulin-dependent diabetes and, in the longer term, a cure.
“Finding a cure for diabetes is part of Novo Nordisk’s vision. Today’s agreement is an important first step in achieving our goal,” Peter Kurtzhals, senior vice president for Diabetes Research at Novo Nordisk, said in a statement.
Stem cells are the body’s master cells, giving rise to all the tissues, organs and blood. Embryonic stem cells are considered the most powerful kinds of stem cells, as they have the potential to give rise to any type of tissue.
Under the terms of the agreement Novo will have exclusive rights to develop and commercialize potential diabetes treatments, while Cellartis has rights to certain other products. Continued…
--------------------------------------------------------------------------------------------Related Posts:
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Researchers trying to find ways to transform ordinary skin cells into powerful stem cells said on Sunday they found a shortcut by “sprinkling” a chemical onto the cells. Adding the chemical allowed the team at the Harvard Stem Cell Institute in Massachusetts to use just two genes
Full Post: Researchers find easier way to make stem cells
--------------------------------------------------------------------------------------------
LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes. An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by
Full Post: European agency rules against stem cell patents
--------------------------------------------------------------------------------------------
By Esha Dey BANGALORE (Reuters) - Shares of companies developing therapies based on stem cells surged on Monday, after confirmation over the weekend that U.S. president-elect Barack Obama plans to reverse an existing executive order against federal funding of embryonic stem-cell research. Companies such as Geron Corp and StemCells Inc saw a sharp rise in their stock
Full Post: Stem-cell firms surge as Obama fuels funding hopes
--------------------------------------------------------------------------------------------
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Stem cell advocates and researchers are eagerly awaiting the moment next year when president-elect Barack Obama rescinds a directive that limits federal funding of human embryonic stem-cell research. The directive was one of President George W. Bush’s first major acts after taking office in 2001, and Obama
Full Post: Stem cell supporters await their Obama moment
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - The U.S. Food and Drug Administration has cleared the way for the world’s first study of human embryonic stem cell therapy, Geron Corp said on Friday. The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord
Full Post: FDA allows first test of human stem cell therapy